The results described above and from other reports indicate that Cdc7 could be a novel effective target for cancer therapy, the inhibition of which might induce cancer cell-specific cell death through novel and distinct pathways in both p53-positive and -negative cancer cells [15], [30]–[32]. Here, TP53 is linked to cancer.